Swiss Medica, Inc.
OTC Bulletin Board : SWME

Swiss Medica, Inc.

August 22, 2005 09:44 ET

Swiss Medica Reports Strong Initial Sales Of New O24 Fibromyalgia At Prohealth.com

TORONTO, ONTARIO--(CCNMatthews - Aug. 22, 2005) -

O24 Fibromyalgia Rockets To Number 3 Spot for Products Sold Through Prohealth.com and receives high praise from consumers using the product

Swiss Medica, Inc. (OTCBB:SWME) today announced that its recently-launched O24 Fibromyalgia pain reliever is enjoying strong sales through the ProHealth medical channel distribution. In early August, ProHealth began offering O24 Fibromyalgia to its customers through its online website, www.prohealth.com - and within days, the product shot straight to the Number 3 spot in terms of volumes of product sold through Prohealth.com.

"We have received very positive feedback from both our Fibromyalgia and general pain audiences regarding 024 Fibromyalgia" says ProHealth President Dennis Schoen. "The product has earned a 4.5 on 1-5 point scale, with 5 being the most efficacious. Customer comments range from benefits for Fibromyalgia symptoms as well as for helping patients dealing with other non-related pain issues."

ProHealth, Inc. the publisher of the largest Fibromyalgia and Chronic Fatigue Syndrome web site, Immune Support.com introduced Swiss Medica's O24 Fibromyalgia product on August 8, 2005. ProHealth's multi-pronged launch of this product, formulated to improve the lives of Fibromyalgia patients, included an emailing to its subscribers and prominent inclusion on Immune Support, where eight million people visited last year for the latest news on Fibromyalgia and Chronic Fatigue Syndrome research, interviews, treatment options and support. Additionally, ProHealth is actively supporting distribution through its network of 5,000 physicians.

The early success of the product has also been warmly received by the National Fibromyalgia Association (NFA). In June, O24 Fibromyalgia became the first product to carry the NFA's new official Seal of Approval.

O24 Fibromyalgia is the first product of its kind developed to specifically address the symptoms of long term pain associated with fibromyalgia syndrome and is a patented and clinically tested, strong and safe, all-natural, over-the-counter health product. Swiss Medica is the owner, maker and distributor of this product. Swiss Medica president, Grant Johnson said that he is highly encouraged by the resoundingly positive response from consumers using the Prohealth.com website. O24 Fibromyalgia will be available in national pharmacies in the United States in the fall of 2005.

"This is a real validation about the demand we see for this product - and it is great to see such strong initial interest from the health care professionals who use ProHealth," he said. "We have known for some time that Fibromyalgia sufferers were crying out for a natural, non-prescription, safe product that could them with pain relief - and we are very happy that we were able to develop it and bring it to market."

Fibromyalgia is typically characterized by widespread musculoskeletal aches, pain and stiffness, soft tissue tenderness, general fatigue and sleep disturbances. The most common sites of pain include the neck, back, shoulders, pelvic girdle and hands. Fibromyalgia patients experience a range of symptoms, varying in intensity that can fluctuate over time. The NFA estimates that the average family doctor sees at least one patient each day who is suffering from fibromyalgia and that the syndrome could cost U.S. economy as much as $10 billion a year in lost productivity.

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com

Swiss Medica's flagship product, the O24™ Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Swiss Medica, Inc.
    Investor Relations Contact:
    David Jones
    (866) 485-4243
    or
    Fusion Communications
    Public Relations Contact:
    Dean Mailey
    (604) 218 6767
    dean@fusioncom.ca
    or
    Stern & Co.
    Financial Media Contact:
    Stan Froelich - VP, Media Relations
    (212) 888-0044
    sfroelich@sternco.com